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Abstract: 
The COMT gene is thought to contribute to the cognitive/psychiatric phenotypes in 22q11.2 
deletion syndrome. We measured these manifestations against the Val/Met alleles of the COMT 
gene, in 40 nonpsychotic 22q11DS children. The Val allele was associated with poor IQ, 
processing speed, executive function and a higher frequency of anxiety disorders, underscoring 
the importance of the COMT gene in the childhood psychopathology in 22q11DS. 
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Article: 
1. Introduction 
Chromosome 22q11.2 deletion syndrome (22q11DS) also known as DiGeorge/velocardiofacial 
syndrome, is associated with childhood deficits in attention, working memory and executive 
functioning; anxiety disorders are also common ( [Gerdes et al., 1999], [Moss et al., 
1999], [Swillen et al., 1997] and [Woodin et al., 2001]). These childhood impairments are 
thought to be related to the 25–40% risk of psychotic disorders in late adolescence/adulthood 
( [Gothelf et al., 2008] and [Shprintzen, 2008]). 
The catechol-O-methyltransferase (COMT) gene located in the 22q11.2 interval has a functional 
polymorphism (Val158Met); homozygosity for Met is associated with 1/3 the enzyme activity in 
Val homozygotes (Chen et al., 2004) and is correlated with better neurocognition in the general 
population ( [Egan et al., 2001] and [Malhotra et al., 2002]) and in schizophrenia ( [Kremer et 
al., 2003] and [Shifman et al., 2002]). Studies of COMT and psychological function in 22q11DS 
individuals have been variable. Met has been reported with decline in verbal ability and working 
memory, AD/HD, obsessive compulsive disorder and bipolar illness ( [Baker et al., 
2005], [Gothelf et al., 2005], [Gothelf et al., 2006], [Lachman et al., 1996] and [Michaelovsky et 
al., 2008]); others report no differences between the Val and Met groups (Glaser et al., 2006). 
Note, however that the above reports included children and adults, as well as psychotic and 
nonpsychotic participants in the same study. Studies including only children with 22q11DS 
found that Val correlated with poor performance in executive function (Kates et al., 2006), 
sustained attention ( [Bearden et al., 2004] and [Shashi et al., 2006]) and more internalizing and 
externalizing behaviors (Bearden et al., 2005). A recent study reported impaired attention with 
the Met allele (Takarae et al., 2009); thus there is a need for further study of these associations. 
We purposefully restricted our study to nonpsychotic children. Based on our previous study 
(Shashi et al., 2006) we hypothesized that children with Met would demonstrate better cognitive 
functioning and behavior relative to Val children. Our preliminary data as well as reports in the 
literature show a high rate (∼ 50%) of anxiety disorders in 22q11DS ( [Baker and Skuse, 
2005], [Gothelf et al., 2007] and [Jolin et al., 2009]) and since anxiety disorders have been 
associated with Val/Met in the general population (Hettema et al., 2008), we examined the 
relationship between these and Val/Met in our cohort. It is to be noted that anxiety disorders are 
a heterogeneous group of disorders and in this manuscript the term anxiety refers to the entire 
group of disorders. 
2. Methods 
The participants were 40 children with 22q11DS, aged 7–16 years. The mean ages of the Met 
and Val groups were 9.3 years (S.D. = 2.3) and 9.8 years (S.D. = 2.8) respectively. All had a 
22q11.2 deletion on FISH testing. A portion of the participants were part of a previous study on 
COMT and cognition (Shashi et al., 2006). 
Neurocognitive assessments included the Wechsler Intelligence Scale for Children, 4th edition 
(Wechsler, 2003) (some of the earlier participants were administered the 3rd edition (Wechsler, 
1999)), Wechsler Individual Achievement Test 2nd edition (Wechsler, 2001), the Continuous 
Performance Test (CPT_IP and _AX) (Cornblatt et al., 1988), the Wisconsin Card Sorting Test 
(WCST) (Harris, 1988), and the California Verbal Learning Test, Children's Version (CVLT) 
(Delis et al., 1994). 
Parents rated their child's behavior using the Child Behavior Checklist (CBCL) (Achenbach and 
Ruffle, 2000) and the Social Skills Rating System (SSRS) (Gresham and Elliot, 1990). The 
Computerized Diagnostic Interview for Children (C-DISC) (NIMH-CDISC, 2004) was 
administered by a licensed clinical psychologist to each child's caregiver. Note that the 
examiners were unaware of the genotype status. 
The COMT Val/Met alleles were ascertained by SNP mapping, using the MassArray system and 
the iPLEX assay from Sequenom, Inc. Statistical analyses were carried out by a t-test, Fisher's 
exact test and Mann–Whitney test. The Val and Met groups were compared with respect to the 
neurocognitive, behavioral and psychiatric manifestations. 
3. Results 
The Met hemizygotes (n = 22) and the Val hemizygotes (n = 18) did not differ in age, gender or 
ethnic composition. Note that corrections for multiple comparisons were not employed given that 
analyses were based on a priori hypotheses. 
Table 1 displays the comparisons of the Val and Met groups on quantitative measures of 
neurocognition and behavior. Reanalyzing the data as 2 (group) × 2 (sex) ANOVAs did not 
change the results; thus gender did not have an effect upon the associations. Furthermore, the 
results were unchanged after excluding the three African-Americans in the study. 
 
Table 1. Comparison of neuropsychological and behavioral manifestations in the Val and Met 
groups (independent samples t-test). 
Test Val/Met n Mean SD t-
value 
Cohen's d P value 
WISC full scale IQ Met 
Val 
21 
18 
76.24 
68.00 
9.55 
11.95 
2.39 0.76 < 0.05 
WISC verbal 
comprehension factor 
Met 
Val 
21 
17 
79.52 
73.71 
11.91 
10.99 
1.55 0.51 0.13 
WISC working 
memory 
Met 
Val 
20 
16 
82.95 
75.06 
10.41 
15.19 
1.85 0.60 0.07 
WISC processing 
speed factor 
Met 
Val 
21 
16 
85.00 
72.88 
15.13 
12.02 
2.61 0.88 < 0.05 
WISC perceptual 
organization factor 
Met 
Val 
22 
17 
78.73 
71.24 
10.72 
15.59 
1.77 0.55 0.08 
WCST conceptual 
level response 
Met 
Val 
22 
17 
84.36 
80.41 
7.73 
14.31 
117.5a  < 0.05 
CBCL social t-score Met 
Val 
17 
14 
45.35 
38.14 
7.19 
8.82 
2.39 0.85 < 0.05 
CBCL 
anxious/depressed 
(III) t-score 
Met 
Val 
18 
14 
56.17 
64.35 
6.24 
9.33 
− 2.98 1.03 < 0.01 
CBCL internalizing t-
score 
Met 
Val 
18 
14 
53.61 
64.07 
15.54 
12.74 
− 2.04 0.74 < 0.05 
Parent SSRS total 
standard score 
Met 
Val 
18 
16 
102.11 
82.5 
13.50 
28.62 
2.60 0.88 0.01 
C-DISC any anxiety 
disorder 
Met 
Val 
5/22 
13/18 
Fisher's exact test P = < 0.01 
 
a Due to violation of the assumption of homogeneity of variance, Mann–
Whitney U statistic computed. Please note that not all tests were performed on all the subjects. 
 
None of the participants had a psychotic disorder, but 25/40 subjects had at least one DSM-IV 
diagnosis (APA, 2000) on the C-DISC. The Val group exceeded the Met group on the rate of any 
diagnosis (P = 0.02). Anxiety disorders were significantly higher with Val (P = <0.01). These 
included in order of Met and Val: specific phobia (n = 5 and n = 9), obsessive compulsive 
disorder (n = 2 and n = 3), separation anxiety (n = 2 and n = 1), social phobia (n = 0 and n = 3), 
generalized anxiety (n = 2 and n = 0), panic disorder (n = 1 andn = 0) and post-traumatic stress 
disorder (n = 0 and n = 6). However, there is no difference between Val and Met groups when 
we tested these anxiety disorders individually. Five of the Met and six of the Val subjects had 
more than one disorder. Note that there is a discrepancy in the number of individuals with Met 
who are listed to have anxiety based on the CBCL in Table 1, compared to those with Met 
(n = 12) who had an anxiety disorder on the C-DISC. Since the C-DISC is a structured 
diagnostic interview, compared to the CBCL which is a parent questionnaire, the results on the 
C-DISC would be more valid. We have formal medical reports as well as verbal confirmation of 
these diagnoses from physicians and parents. There were no differences between Val and Met 
groups in the occurrence of depression or AD/HD, or in medication status for anxiety disorder or 
AD/HD. 
4. Discussion 
The relation of COMT with psychological functioning in children with 22q11DS has been 
equivocal. We found that children who are hemizygous for Met have superior cognitive 
functioning and diminished behavioral problems relative to children hemizygous for Val. 
Additionally, we are the first to report that the Val allele is associated with anxiety disorders in 
22q11DS children. 
Within the general population, Met homozygosity is often reported to confer a cognitive 
advantage in healthy individuals and in schizophrenia ( [Bilder et al., 2002], [Diamond et al., 
2004], [Egan et al., 2001], [Enoch et al., 2009], [Houlihan et al., 2009], [Joober et al., 
2002] and [Malhotra et al., 2002]) . For 22q11DS patients, associations of the Val/Met genotype 
and psychological deficits have been contradictory, with reports of Met being advantageous on 
intelligence and higher neurocognition ( [Bearden et al., 2004], [Kates et al., 2006] and [Shashi 
et al., 2006]); reports of no association with intelligence ( [Baker et al., 2005], [Glaser et al., 
2006] and [van Amelsvoort et al., 2008]) and reports of Met being associated with a decline in 
verbal IQ (Gothelf et al., 2005). We found that Met hemizygosity is associated with better 
cognitive performance in 22q11DS children. It may be that this relation changes with age, such 
that the Met becomes associated with poorer cognition, consistent with the proposed inverted U-
shaped relationship between PFC dopamine levels and function ( [Barnett et al., 
2009], [Goldman-Rakic et al., 2000] and [Mattay et al., 2003]). Indeed, most studies of 22q11DS 
children less than 16 years found that neurocognition is superior with Met ( [Bearden et al., 
2004], [Kates et al., 2006] and [Shashi et al., 2006]). Studies including older 22q11DS subjects 
reported that Val posed a cognitive advantage ( [Baker et al., 2005] and [Bassett et al., 2007]). 
Other factors that could account for such varying reports include small sample sizes, inclusion of 
both psychotic and nonpsychotic individuals, differences in neuropsychological measures, 
effects of linkage disequilibrium with another genetic variant in this interval, interactions 
between COMT and other genes (Vorstman et al., 2009), impact of stress upon frontal dopamine 
levels and ethnicity differences in genotypes. We did not see differences on tests of sustained 
attention and verbal learning between Val and Met in our study. This may be because these are 
not pure tests of prefrontal cognition, with the anterior cingulate modulating sustained attention 
and verbal memory involving the temporal lobe. 
The relation between Val/Met and childhood psychiatric diagnoses in 22q11DS is poorly 
delineated. Met was associated with elevated rates of AD/HD (Gothelf et al., 2006); in the same 
subjects AD/HD and OCD were associated with a larger haplotype within COMT, including Met 
(Michaelovsky et al., 2008). However, these samples included subjects 6–26 years in age and a 
mix of psychotic and nonpsychotic participants. We found no evidence of an association between 
Val/Met and AD/HD in our cohort, similar to a meta-analysis in the general population (Cheuk 
and Wong, 2006). 
Our finding of an association between Val and anxiety disorders may suggest that similar to 
neurocognition, the influence of COMT on anxiety disorders in 22q11DS may be age dependent, 
consistent with a report that Val was associated with higher internalizing behaviors in 22q11DS 
children (Bearden et al., 2005). A definite association of the Val allele with anxiety disorders in 
children in the general population has not been established (Gadow et al., 2009) while in adults 
the Met allele is often found to be associated with anxiety (Drabant et al., 2006). Nevertheless, 
our finding provides an important baseline indicator that warrants replication and longitudinal 
study. 
The strengths of our study include the use of nonpsychotic children with 22q11DS, a reasonable 
sample size given the difficulty of recruiting from this population and the inclusion of 
neurocognitive measures recommended by the NIMH-MATRICS task force ( [Kern et al., 
2004] and [Nuechterlein, 2006]). The limitations of the study are that it is possible that our 
results may be related to linkage disequilibrium with other genetic variants in this interval and 
due to our sample size the power was 62%. 
In conclusion, we demonstrated that the Met allele is associated with better neurocognition and 
lower frequency of anxiety disorders in nonpsychotic children with 22q11DS. Longitudinal 
studies of this cohort should facilitate understanding of the developmental trajectories associated 
with Val/Met hemizygosity. 
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